NSEOutcome of Board Meeting10h ago · 3 Sept 2026, 08:11 pm
Outcome of Board Meeting
Orchid Pharma Limited · ORCHPHARMA
✦ AI SummaryMgmt Change
Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026, where the Board of Directors approved the appointment of Cost Auditors for FY 2026-27, appointment of Mr. Arjun Dhanuka as Whole-Time Director, and other matters.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern5/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Attachments (1)
📄pdf
Download →
ORCHPHARMA_03092026200939_Stx_ltr_outcome_sd.pdf
View document text
OrchidPharm~W
September 03, 2026
National Stock Exchange of India Limited, BSE Limited
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal
Bandra (E), Mumbai-400051 Street, Fort, Mumbai-400001
Symbol: ORCHPHARMA Scrip Code: 524372
Subject: Outcome of Board Meeting - Orchid Pharma Limited ("the Company")
Dear SirjMadam,
With reference to the captioned subject and pursuant to Regulation 30 read with Schedule III
of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Master Circular no.
SEBIj HOj49j14j14(7)2025-CFD-POD2jI/3762j2026, dated January 30, 2026, we would like
to inform you that the Board of Directors of the Company at its meeting held today i.e.
September 03, 2026 (commenced at 18:00 P.M. (IST) and concluded at 19:45 P.M. (IST) has
inter-alia considered and approved below mentioned matters:
1. Appointment and recommendation of remuneration of Cost Auditors of the Company for the
F.Y. 2026-27. Details as required under Regulation 30 read with SEBI Circular SEBIj
HOj49j14j14(7)2025-CFD-POD2jI/3762j2026, dated January 30, 2026 are enclosed
herewith as Annexure-I
2. Appointment and remuneration of Mr. Arjun Dhanuka (DIN: 00454689) as Whole-Time
Director, who is presently a Non-Executive Non Independent Director of the company.
Details as required under Regulation 30 read with SEBI Circular SEBI/
HOj49j14j14(7)2025-CFD-POD2jI/3762j2026, dated January 30, 2026 are enclosed
herewith as Annexure-II
3. Notice, including explanatory statement therein, for convening 33rd Annual General Meeting
of the Company scheduled to be held on September 29, 2026.
4. The cut-off date for determining the shareholders eligible of receiving the notice of ensuing
Annual General Meeting scheduled to be held on September 29, 2026, shall be Friday,
September 04, 2026 and for e-voting i.e. shareholders eligible to vote on the resolutions in
notice of Annual General Meeting, shall be Tuesday, September 22, 2026. The Remote e
voting period will commence on September 26, 2026 (9:00 A.M. 1ST) and ends on
September 28, 2026 (5:00 P.M. 1ST).
5. Appointment of e-voting agency for facilitating e-voting including remote e-voting and the
appointment of scrutinizer for providing scrutinizer's report thereon.
You are requested to take the above intimations on record.
Thanking You,
For Orchid Pharma Limited
KapilOayya
Company Secretary & Compliance Officer
Mem. No.- Fl0698
Encl. as above
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
OrchidPharm~W
Annexure- I
Information as required under Regulation 30 - Para A of Part A of Schedule III of
SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with
SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated
January 30, 2026
(Appointment of Auditor)
Particulars Appointment of Cost Auditor for FY
2026-2027
Name of the Audit Firm/Auditor M/s. J Karthik~an & Associates
Reason for change viz. a ppoi ntment, Appointment
resignation, removal, death or
other'wise.
Date of appointment & Term of The Board at their meeting held today i.e.
appointment September 03, 2026, 2025, approved the
appointment of Cost auditor for the
F.Y.2026-27, subject to the ratification of
remuneration of the cost auditor by the
Members of the Company at the ensuing
AGM.
Brief Profile M/s. J Karthikeyan & Associates, Cost
Accountant, Chennai, holding Certificate
of Practice issued by the Institute of Cost
Accountants of India (Membership No.29934,
Firm Registration No.l02695) .
Disclosure of relationships between Nil
Directors
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
OrchidPharm~W
Annexure- II
Information as required under Regulation 30 - Para A of Part A of Schedule III of
SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with
SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/1/3762/2026, dated
January 30, 2026
Sr. Particulars Information w.r.t Mr. Arjun
No. Dhanuka
1 Reason for change viz. appointment, Change in designation
resignation, removal, death or otherwise
2 Date of appointment/cessation (as September 03, 2026
applicable) & term of appointment Tenure- September 03, 2026 to
September 02, 2031
3 Brief profile (in case of appointment) Mr. Arjun Dhanuka started his career
with Dhanuka Laboratories Limited in
September 2010. From 2010-13 his
role comprised of managing all the
purchase decisions of the Company.
He graduated from Delhi University
and has served as Whole Time
Director of Dhanuka Laboratories
Limited.
In 2013, he started working with
operations team of Synmedic
Laboratories. After gaining relevant
experience, he supervised majority
of operations at Synmedic
Laboratories since 2020. He strives
in Business Development and
strategy building. Mr. Dhanuka is
young and dynamic person with an
experience of more than a decade in
the Pharmaceuticals Sector.
4 Disclosure of relationships between As per sec 2 (76) of Companies Act
directors (in case of appointment of a 2013, Mr. Arjun Dhanuka is no
director) related to other Directors and Key
Managerial Personnel of the Company
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1. DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.